Neuland Laboratories Limited
NSE: NEULANDLABINE794A01010·HealthcareSmallcap 250·www.neulandlabs.com ↗·Mcap ₹28,859 Cr·Listed 2008
₹21,890.00▼ ₹15.00  (−0.07%)
52W: ₹11,500 – ₹24,225 · Vol: 42.0K shares · Close 25 Sept
Set Alert

Quarterly results

consolidated · as filed with NSE · Q1 FY27 back to Q4 FY17
₹ croreQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24Q4 FY23Q3 FY23Q2 FY23Q1 FY23Q4 FY22Q3 FY22Q2 FY22Q1 FY22Q4 FY21Q3 FY21Q2 FY21Q1 FY21Q4 FY20Q3 FY20Q2 FY20Q4 FY17
Revenue from operations6427764405142933283983114403853934183634072692942212562362582012452452412051922041860
Other income8.512.58.11.87.97.53.94.34.85.42.1328.10.90.20.50.61.90.32.114.60.20.60.71.810.60
Total expenses4525013933872832973302663352982902992823052312412082322202311912352142131861761891740
EBITDA22330777.115634.551.186.662.212310712113796.912054.169.328.638.932.442.825.725.546.640.933.830.128.224.90
EBITDA margin34.7%39.6%17.5%30.2%11.8%15.6%21.8%20.0%28.1%27.8%30.9%32.9%26.7%29.4%20.1%23.6%12.9%15.2%13.7%16.6%12.8%10.4%19.0%16.9%16.5%15.7%13.8%13.4%–
Finance costs77.26.85.44.62.32.21.12.73.63.74.42.24.32.73.22.92.83.33.63.84.64.43.55.47.15.74.80
Depreciation26.625.123.922.520.216.916.316.116.316.515.114.513.613.513.313.212.812.512.81211.811.110.49.38.97.67.88.30
Profit before tax19828754.512917.639.312849.413092.210412283.211038.953.213.524.318.227.612.124.431.928.720.317.215.712.50
Tax50.274.813.932.63.711.526.216.63224.623.132.321.325.68.414.73.52.55.37.23.37.15.27.25.126.54.63.80
Net profit14821340.696.913.927.810232.897.967.681.489.261.984.530.538.51021.812.920.48.717.326.721.415.2−9.311.18.70
Net margin23.0%27.4%9.2%18.8%4.7%8.5%25.5%10.6%22.3%17.5%20.7%21.4%17.0%20.8%11.3%13.1%4.5%8.5%5.5%7.9%4.3%7.1%10.9%8.9%7.4%-4.9%5.5%4.7%–
EPS (₹)115.10165.7631.6275.4910.8321.6779.1825.6076.2852.6663.4469.5648.2365.9023.8129.977.7717.0110.0815.886.8113.4820.8416.7111.82-7.258.666.770.00
Net profit YoY+962.4%+664.8%−60.1%+194.9%−85.8%−58.8%+24.8%−63.2%+58.2%−20.1%+166.4%+132.1%+520.9%+288.2%+136.2%+88.8%+14.1%+26.0%−51.6%−5.0%−42.4%+286.0%+140.6%+146.8%–––––

Annual results

financial years ending March · from the fourth-quarter filings
₹ croreFY26FY25FY24FY23FY22FY21FY20FY17
Revenue from operations2,0231,4771,5591,1919519377630
Other income30.220.512.59.72.116.13.90
Total expenses1,5641,2271,1709858718487140
EBITDA5743234632721431471020
EBITDA margin28.4%21.9%29.7%22.8%15.0%15.7%13.4%–
Finance costs23.98.31413.113.517.921.60
Depreciation91.765.559.752.84939.731.30
Profit before tax48934640121682.210552.90
Tax12586.210152.218.324.736.70
Net profit36426030016463.880.616.20
Net margin18.0%17.6%19.3%13.7%6.7%8.6%2.1%–
EPS (₹)283.71202.74233.89127.4549.7462.8512.630.00
Net profit YoY+39.9%−13.3%+83.5%+156.2%−20.8%+397.4%––
EPS is as filed for each period and is not restated for later bonus issues or splits.

Cash flow

annual · ₹ crore
₹ croreFY26FY25FY24FY23FY22
Operating cash flow34731726123758.6
Investing cash flow−424−298−150−61.5−93.7
Financing cash flow2125−69.3−13637.7
Capital expenditure39020614165.795.9
Free cash flow (CFO − capex)−43.5111120172−37.3

Net profit trend

annual, ₹ crore
FY21
₹80.6
FY22
₹63.8−21%
FY23
₹164+156%
FY24
₹300+84%
FY25
₹260−13%
FY26
₹364+40%

Result filings

as filed with NSE · PDF and XBRL
PeriodBasisFiledDocuments
Q1 FY27Consolidated5 Aug 2026PDF on NSE XBRL
Q1 FY27Standalone5 Aug 2026PDF on NSE XBRL
Q4 FY26Consolidated · audited12 May 2026PDF on NSE XBRL
Q4 FY26Standalone · audited12 May 2026PDF on NSE XBRL
Q3 FY26Consolidated9 Feb 2026PDF on NSE XBRL
Q3 FY26Standalone9 Feb 2026PDF on NSE XBRL
Q2 FY26Consolidated7 Nov 2025PDF on NSE XBRL
Q2 FY26Standalone7 Nov 2025PDF on NSE XBRL
Q1 FY26Consolidated31 Jul 2025PDF on NSE XBRL
Q1 FY26Standalone31 Jul 2025PDF on NSE XBRL

Annual reports

NSE archive
Key ratios
P/E (TTM)5Y avg 36.0×56.7×
P/B5Y avg 7.06×15.07×
ROEFY26, on average equity21.4%
Net margin18.0%
Debt / equity0.10×
Revenue CAGR (3Y)19.3%
Profit CAGR (3Y)30.6%
EPS (TTM)₹385.85
Market cap₹28,239 Cr
Computed from the filings and the last close. Market cap uses the latest share count from the balance sheet.
P/B vs history
15.07×
vs 8-point avg 7.06× (+113%)
1.99× low7.06× avg15.07× high
History points are balance-sheet dates (2022 → 2026), priced at the adjusted close on each date.
Balance sheet 31 Mar 2026
Total assets₹2,930 Cr+34%
Net worth₹1,874 Cr+23%
Total borrowings₹197 Cr+45%
Cash & bank balances₹77 Cr−42%
Investments₹2 Cr−98%
Inventories₹510 Cr+32%
Trade receivables₹541 Cr+71%
Trade payables₹269 Cr+7%
Change vs the same date a year earlier.
Revenue mix Q3 FY26
USA and North America43.6%result ₹0 Cr
Europe27.7%result ₹0 Cr
India20.8%result ₹0 Cr
Rest of the world7.8%result ₹0 Cr
Segment revenue as reported, before inter-segment eliminations.
Shareholding 30 Jun 2026
%Jun 26Mar 26Dec 25Sept 25Jun 25Mar 25Dec 24Sept 24Jun 24Mar 24Dec 23Sept 23
Promoter32.6232.6332.6332.6432.6832.6832.6832.6432.7232.7432.8035.97
FII21.0820.4620.9020.6021.6922.1123.8626.4625.7224.4422.6921.57
DII16.5115.8414.7113.5411.5710.979.086.386.396.546.036.99
of which MF12.6611.3510.399.787.66–––––––
Retail22.8823.8524.3124.7225.5525.8626.0426.5027.0527.9729.5227.86
Other public6.917.227.458.508.518.388.348.028.128.318.967.61
44,340 shareholders · NSE shareholding pattern filings.